Espranor (buprenorphine oral lyophilisate) / Ethypharm - LARVOL DELTA

Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy. (PubMed, Pharmaceuticals (Basel)) - "Oral methadone and sublingual and depot buprenorphine are the undisputed gold standard in opioid agonist treatment (OAT). BUP-Lyo expands the range of available buprenorphine formulations and offers practical advantages through accelerated absorption and simplified administration. While initial data are encouraging, the limited evidence base underscores the need for further longitudinal and post-marketing studies to define its clinical position in the management of OUD."

Journal • Review • Addiction (Opioid and Alcohol) • Psychiatry • Substance Abuse

EXPO: Extended-release Pharmacotherapy for Opioid Use Disorder (clinicaltrials.gov) - P3 | N=342 | Completed | Sponsor: King's College London | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2023

Trial completion • Trial completion date • Substance Abuse

EXPO: Extended-release Pharmacotherapy for Opioid Use Disorder (clinicaltrials.gov) - P3 | N=342 | Active, not recruiting | Sponsor: King's College London | Recruiting ➔ Active, not recruiting | N=604 ➔ 342

Enrollment change • Enrollment closed • Substance Abuse

EXPO: Extended-release Pharmacotherapy for Opioid Use Disorder (clinicaltrials.gov) - P3; N=604; Recruiting; Sponsor: King's College London

Clinical • New P3 trial • Substance Abuse